MetaCap

CDT Equity (CDT) vs Matinas Biopharma (MTNB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Matinas Biopharma is the larger company by market cap ($890,711 vs $437,033), about 2.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CDT-72.49%MTNB-71.12%
+64%-19%-103%
Oct 7, 20261 yearNov 20, 2026
CDT-67.97%MTNB-72.13%
+91%-4%-99%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CDT versus MTNB key metrics
MetricCDTMTNB
Share price$0.23$0.7999
Market cap$437.03K$890.71K
1-day change-13.89%-1.26%
P/E ratio (TTM)0.00—
EPS (TTM)$1,816,250.00$-17.55
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-39.22M$-10.35M
52-week high$291,250.00$14.63
52-week low$0.223$0.75
Distance from 52-week high-100.00%-94.53%
Average volume956.66K80.86K
Shares outstanding1.90M1.11M
Employees42
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Matinas Biopharma is about 2.0 times larger than CDT Equity by market value ($890.71K vs $437.03K).

About CDT Equity

CDT stock →

CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

About Matinas Biopharma

MTNB stock →

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

CDT vs MTNB FAQ

Which is bigger, CDT Equity or Matinas Biopharma?

Matinas Biopharma (MTNB) is larger, with a market capitalization of $890.71K compared with $437.03K for CDT Equity (CDT).

Are CDT Equity and Matinas Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons